Cargando…
Humoral and Cellular Immune Responses of People Living With Human Immunodeficiency Virus After 3 Doses of Messenger RNA BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine: A Prospective Cohort Study
BACKGROUND: Recent studies have shown good serological and cellular immune responses in people living with human immunodeficiency virus (PLWH) after receipt of 2 doses of messenger RNAA (mRNA) severe acute respiratory syndrome coronavirus 2 vaccine. Data are missing regarding the response after 3 va...
Autores principales: | Tau, Luba, Hagin, David, Freund, Tal, Halperin, Tamar, Adler, Amos, Marom, Rotem, Ahsanov, Svetlana, Matus, Natasha, Levi, Inbar, Gerber, Gal, Lev, Shir, Ziv-Baran, Tomer, Turner, Dan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394980/ https://www.ncbi.nlm.nih.gov/pubmed/37539062 http://dx.doi.org/10.1093/ofid/ofad347 |
Ejemplares similares
-
SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical Center
por: Tau, Luba, et al.
Publicado: (2022) -
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity
por: Hagin, David, et al.
Publicado: (2021) -
Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients
por: Pri-Paz Basson, Yael, et al.
Publicado: (2022) -
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
por: Herishanu, Yair, et al.
Publicado: (2022) -
Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy—A Single Center Prospective Cohort Study
por: Ram, Ron, et al.
Publicado: (2022)